摘要
Background: Mycoplasma hominis and Ureaplasma urealyticum are opportunistic pathogens frequently encountered in the female genital tract. They are involved in various infections that can lead to serious complications such as pregnancy complications, spontaneous abortions, bacterial vaginosis, salpingitis, and infertility. Syndromic management is common, but monitoring antibiotic sensitivity is crucial to limit the emergence and spread of resistant strains. Methodology: A descriptive and cross-sectional study was conducted at the Clinique Médico-Chirurgicale COGEMO in Brazzaville between January 2019 and December 2021, involving 162 sexually active women followed up in the gynecology-obstetrics department. Duplicate endocervical samples were collected and analyzed using the Mycoplasma AF Genital System kit (Liofilchem) to identify Mycoplasma hominis and Ureaplasma urealyticum, as well as their sensitivity profiles to fluoroquinolones, macrolides, and tetracyclines. Results: The prevalence of genital mycoplasmas was 21.6%. Ureaplasma urealyticum was detected in 10.49% of the samples, Mycoplasma hominis in 3.08%, and co-infections in 8.02%. Women infected with Ureaplasma urealyticum were generally in a couple, aged 28 to 37 years, unemployed, and asymptomatic. For Mycoplasma hominis, the profile was similar but with a wider age range of 18 to 47 years. Mycoplasma hominis showed high resistance to pefloxacin (80%), erythromycin (60%), tetracycline (60%), and doxycycline (60%). In co-infections, resistances were 61.4% for erythromycin and 53.85% for tetracycline. Ureaplasma urealyticum showed a sensitivity significantly higher than 20% for all tested antibiotic molecules. Conclusion: This study highlights the high prevalence of Mycoplasma hominis and Ureaplasma urealyticum in the female genital tract and their concerning resistance to antibiotics. Mycoplasma hominis shows high resistance while Ureaplasma urealyticum presents better sensitivity, though still notable. The variability of observed sensitivity profiles underscores the need for personalized therapeutic approaches based on updated data to protect women’s reproductive health.
Background: Mycoplasma hominis and Ureaplasma urealyticum are opportunistic pathogens frequently encountered in the female genital tract. They are involved in various infections that can lead to serious complications such as pregnancy complications, spontaneous abortions, bacterial vaginosis, salpingitis, and infertility. Syndromic management is common, but monitoring antibiotic sensitivity is crucial to limit the emergence and spread of resistant strains. Methodology: A descriptive and cross-sectional study was conducted at the Clinique Médico-Chirurgicale COGEMO in Brazzaville between January 2019 and December 2021, involving 162 sexually active women followed up in the gynecology-obstetrics department. Duplicate endocervical samples were collected and analyzed using the Mycoplasma AF Genital System kit (Liofilchem) to identify Mycoplasma hominis and Ureaplasma urealyticum, as well as their sensitivity profiles to fluoroquinolones, macrolides, and tetracyclines. Results: The prevalence of genital mycoplasmas was 21.6%. Ureaplasma urealyticum was detected in 10.49% of the samples, Mycoplasma hominis in 3.08%, and co-infections in 8.02%. Women infected with Ureaplasma urealyticum were generally in a couple, aged 28 to 37 years, unemployed, and asymptomatic. For Mycoplasma hominis, the profile was similar but with a wider age range of 18 to 47 years. Mycoplasma hominis showed high resistance to pefloxacin (80%), erythromycin (60%), tetracycline (60%), and doxycycline (60%). In co-infections, resistances were 61.4% for erythromycin and 53.85% for tetracycline. Ureaplasma urealyticum showed a sensitivity significantly higher than 20% for all tested antibiotic molecules. Conclusion: This study highlights the high prevalence of Mycoplasma hominis and Ureaplasma urealyticum in the female genital tract and their concerning resistance to antibiotics. Mycoplasma hominis shows high resistance while Ureaplasma urealyticum presents better sensitivity, though still notable. The variability of observed sensitivity profiles underscores the need for personalized therapeutic approaches based on updated data to protect women’s reproductive health.
作者
Mireille Jeanine Sita Maboundou Bitsi
Esther Nina Ngoyi Ontsira
Tanguy Mieret
Bonaventure Max Lazare Peneme
Victange Venceslas Géraud Nionia
Fils Landry Mpele
Narcisse Ngangoue
Junior Patrick Sergy Bissoko
Mireille Jeanine Sita Maboundou Bitsi;Esther Nina Ngoyi Ontsira;Tanguy Mieret;Bonaventure Max Lazare Peneme;Victange Venceslas Géraud Nionia;Fils Landry Mpele;Narcisse Ngangoue;Junior Patrick Sergy Bissoko(Technical and Scientific Faculty, Marien NGOUABI University, Brazzaville, Congo;Health Sciences Faculty, Marien NGOUABI University, Brazzaville, Congo;Bacteriology-Virology Laboratory, University Hospital Center, Brazzaville, Congo;National Public Health Laboratory, Brazzaville, Congo;Gynecology-Obstetrics Department, Referral Hospital Center of Mfilou, Brazzaville, Congo;UNDP Laboratory, Brazzaville, Congo;Laboratory of the Clinic Medico Chirurgical COGEMO, Brazzaville, Congo)
